Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eatOCfbwoceUdWpVMKaj

November 27, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • Survey of biotech startups finds tough financing landscape
    Perhaps as few as 28 life sciences companies in North America and the U.K. raised at least $5 million in a first-time financing in 2012, writes Luke Timmerman. Of the companies he identified, seven were based in Boston and five in San Francisco. "Any way you choose to look at it, there is so little money now being put into biotech startups that any rational person has to wonder where the new drugs, medical devices, and diagnostics are going to come from in the 2020s and beyond," he writes. Xconomy (11/26) LinkedInFacebookTwitterEmail this Story
Can New Diabetes Therapies Solve an Out-of-Control Epidemic?
The statistics are just plain scary. New estimates released by the International Diabetes Federation (IDF) to mark World Diabetes Day 2012 last week say that 371 million people have diabetes and 187 million diabetes cases remain undiagnosed. The IDF data means that millions of people are at risk of costly and debilitating diabetes complications. Find out the details.

  Health Care & Policy 
 
  • ERYtech licenses leukemia treatment to European drugmaker
    ERYtech Pharma granted Recordati the rights to sell Graspa, an experimental drug for leukemia, in Europe. The drug, a formulation of L-asparaginase, is being evaluated in a Phase II/III study for acute lymphoblastic leukemia and will soon enter a midstage trial for acute myeloid leukemia. Graspa has orphan-drug status for acute lymphoblastic leukemia in the U.S. and Europe. PharmaTimes (U.K.) (11/26) LinkedInFacebookTwitterEmail this Story
  • Sarepta, partners seek to develop drug for rare neuromuscular disorder
    Sarepta Therapeutics said it is working with several organizations and scientists to develop a fourth treatment for the rare neuromuscular condition Duchenne muscular dystrophy. The project is prompted partly by positive results of a midstage trial of Sarepta's lead drug candidate eteplirsen. The goal of the collaboration is to develop a drug that would skip exon 53, a DNA sequence, to address a genetic mutation linked to 13% of DMD cases. Mass High Tech (Boston) (11/26) LinkedInFacebookTwitterEmail this Story
Reimagine the life science patient experience
The life science industry is undergoing rapid transformation, driven by consumer empowerment, clinical innovation and outcomes-driven health care policy. In this changing landscape, medical device and pharmaceutical companies are striving to connect with patients and deliver the best possible experience before, during and after therapy. Learn more.
ADVERTISEMENT
  Company & Financial News 
  • CPP hopes to raise $5M ahead of colon cancer prevention drug trials
    Cancer Prevention Pharmaceuticals wants to raise $5 million in advance of additional clinical trials for a colorectal cancer prevention drug made up of CPP-1X/sul, known as Eflornithine, and sulindac, an NSAID. The drugs are thought to interfere with pathways linked to cancer risk, and the company said early studies showed they cut the recurrence of colon polyps linked to cancer by 92%. MedCityNews.com (11/23) LinkedInFacebookTwitterEmail this Story
  Global Developments 
  • Galapagos discovers novel class of antibiotics that kill all MRSA strains
    Belgian biotech firm Galapagos said it has identified a new class of antibiotics that demonstrate strong activity against drug-resistant strains of Staphylococcus aureus, including MRSA. The antibiotic acts against an enzyme that is key to the growth of all bacteria, the company said. Galapagos said clinical studies could begin for the antibiotic candidate CAM-1 in early 2014. Examiner.com (11/26) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Industrial & Environmental 
  • Opinion: Competition with China may benefit U.S. biofuels
    A healthy dose of competition from China or Brazil could spur greater support for the U.S. biofuels industry, in the same way that the space race with the Soviet Union boosted support for the U.S. aerospace industry, writes Susanne Retka Schill. The Chinese government has been pursuing its own "all of the above" energy agenda, and some Chinese investors may soon make their presence felt in the advanced biofuels sector, she writes. EthanolProducer.com/Throughput Blog (11/26) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
Every path hath a puddle."
--George Herbert,
Welsh-British poet, orator and priest


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information